Entegris Total Cost of Revenue decreased by 7.0% to $431.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.5%, from $416.70M to $431.10M. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 9.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $305.97M | $315.29M | $340.11M | $339.83M | $382.09M | $622.16M | $541.55M | $520.71M | $516.83M | $521.17M | $467.59M | $419.20M | $436.90M | $435.90M | $462.50M | $416.70M | $440.90M | $455.80M | $463.30M | $431.10M |
| QoQ Change | — | +3.0% | +7.9% | -0.1% | +12.4% | +62.8% | -13.0% | -3.8% | -0.7% | +0.8% | -10.3% | -10.3% | +4.2% | -0.2% | +6.1% | -9.9% | +5.8% | +3.4% | +1.6% | -7.0% |
| YoY Change | — | — | — | — | +24.9% | +97.3% | +59.2% | +53.2% | +35.3% | -16.2% | -13.7% | -19.5% | -15.5% | -16.4% | -1.1% | -0.6% | +0.9% | +4.6% | +0.2% | +3.5% |